Cytotoxicity reduction by O-nicotinoylation of antiviral 6-benzylaminopurine ribonucleosides.

6-Benzylaminopurine ribonucleosides Antiviral activity Biodegradable lipophilic groups Cytotoxicity reduction Enterovirus EV-A71 O-Nicotinoylation

Journal

Toxicology in vitro : an international journal published in association with BIBRA
ISSN: 1879-3177
Titre abrégé: Toxicol In Vitro
Pays: England
ID NLM: 8712158

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 17 01 2022
accepted: 30 03 2022
pubmed: 8 4 2022
medline: 7 6 2022
entrez: 7 4 2022
Statut: ppublish

Résumé

One of the promising approaches in the development of nucleoside prodrugs is to use the nucleoside analogs containing lipophilic biodegradable residues, which are cleaved to biologically active forms after metabolic transformations in the cell. The introduction of such fragments makes it possible to reduce the general toxicity of the drug candidate and increase its stability in the cell. In order to study the influence of biodegradable lipophilic groups on antiviral activity and cytotoxicity, in this work we synthesized N

Identifiants

pubmed: 35390475
pii: S0887-2333(22)00052-2
doi: 10.1016/j.tiv.2022.105355
pii:
doi:

Substances chimiques

Antiviral Agents 0
Benzyl Compounds 0
Nucleosides 0
Prodrugs 0
Purines 0
Ribonucleosides 0
Adenosine K72T3FS567
benzylaminopurine KXG6A989PS

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105355

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Anastasia A Zenchenko (AA)

Engelhardt Institute of Molecular Biology, Moscow 119991, Russia.

Vladimir E Oslovsky (VE)

Engelhardt Institute of Molecular Biology, Moscow 119991, Russia.

Irina V Varizhuk (IV)

Engelhardt Institute of Molecular Biology, Moscow 119991, Russia.

Evgenia V Karpova (EV)

FSASI "Chumakov FSC R&D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.

Dmitry I Osolodkin (DI)

FSASI "Chumakov FSC R&D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.

Liubov I Kozlovskaya (LI)

FSASI "Chumakov FSC R&D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.

Aydar A Ishmukhametov (AA)

FSASI "Chumakov FSC R&D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.

Mikhail S Drenichev (MS)

Engelhardt Institute of Molecular Biology, Moscow 119991, Russia. Electronic address: room517@eimb.ru.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH